Background Thrombolytic therapy is usually reserved for patients with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Background Thrombolytic therapy is usually reserved for people with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Objectives: We sought to assess the efficacy and safety of thrombolytic therapy in patients
with an acute pulmonary embolism (PE). Background: Thrombolytic therapy is approved for …

Background—Randomized trials and meta-analyses have reached conflicting conclusions
about the role of thrombolytic therapy for the treatment of acute pulmonary embolism …

Background In patients with acute pulmonary embolism, thrombolysis results in a more rapid
resolution of pulmonary emboli than heparin treatment. Whether this advantage results in an …

Pulmonary embolism (PE) is a common disorder that is accompanied by significant
morbidity and mortality. Although anticoagulation is the standard treatment for PE …

Aim Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with
acute pulmonary embolism (PE) but is associated with an increased risk of haemorrhage …

Importance Thrombolytic therapy may be beneficial in the treatment of some patients with
pulmonary embolism. To date, no analysis has had adequate statistical power to determine …

Acute pulmonary embolism represents a major complication of venous thromboembolism
that is associated with high morbidity and mortality. Guidelines recommend the rapid …

Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary
embolism (PE). However, the safest and most effective treatment is as yet unknown. In the …